Aandeel GMTX GEMI THER
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen GEMI THER

Aandelen

GMTX

US36870G1058

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Arix portfolio firm Disc Medicine seals Gemini Therapeutics merger
DISC MEDICINE, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from NASDAQ Composite Index
Disc Medicine, Inc. completed the acquisition of Gemini Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.
GEMINI THERAPEUTICS, INC. /DE : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
Gemini Therapeutics Shares Rise After Disc Medicine Gets FDA Designation
GEMINI THERAPEUTICS, INC. /DE : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Gemini Therapeutics' Disc Medicine Secures FDA's Orphan Drug Status for Erythropoietic Protoporphyria Treatment
Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
GEMINI THERAPEUTICS, INC. /DE : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
GEMINI THERAPEUTICS, INC. /DE : Change in Directors or Principal Officers (form 8-K)
GEMINI THERAPEUTICS, INC. /DE Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Gemini Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
GEMINI THERAPEUTICS, INC. /DE : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from S&P Global BMI Index
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
GEMINI THERAPEUTICS, INC. /DE Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Gemini Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Arix Bioscience To Invest $54 Million To Fund All-stock Disc Medicine, Gemini Therapeutics Merger
Conference Call Transcript Gemini Therapeutics and Disc Medicine Merger Agreement Announcement August 10, 2022 / 08:00 AM ET - Form 8-K
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers GMTX
  4. Nieuws GEMI THER
  5. Andere talen